Key Points
- COO Michael Chi sold 97,289 shares on March 17 at an average price of $24.69 for a total of $2.40 million, trimming his stake by 19.28% to 407,282 shares (about $10.06 million); the sale was disclosed in an SEC Form 4 filing.
- Hims & Hers reported Q4 EPS of $0.08 (vs. $0.02 estimate) and revenue of $617.8M (slightly below estimates) with revenue up 28.4% year‑over‑year, while the stock has recently traded down and sits at a market cap of roughly $5.3B with a PE of 45.6.
- Strategic catalysts include a partnership with Novo Nordisk to run a pre‑launch GLP‑1 waitlist, but near‑term sentiment is mixed due to insider selling, GLP‑1 pricing competition risks, and a consensus analyst rating of "Hold" (average target ~$31.29).
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) COO Michael Chi sold 97,289 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the sale, the chief operating officer owned 407,282 shares in the company, valued at $10,055,792.58. The trade was a 19.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Hims & Hers Health Trading Down 7.0%
NYSE HIMS opened at $23.23 on Thursday. The company has a market capitalization of $5.30 billion, a PE ratio of 45.55, a P/E/G ratio of 2.80 and a beta of 2.55. The company has a fifty day moving average of $23.19 and a 200 day moving average of $36.98. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. The company had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm's revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period last year, the firm earned $0.11 EPS. Research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.
Hedge Funds Weigh In On Hims & Hers Health
Hedge funds have recently bought and sold shares of the business. VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in shares of Hims & Hers Health by 0.8% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company's stock worth $1,452,000 after acquiring an additional 200 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Hims & Hers Health by 6.1% during the 3rd quarter. GAMMA Investing LLC now owns 4,098 shares of the company's stock valued at $232,000 after acquiring an additional 236 shares during the last quarter. Concurrent Investment Advisors LLC grew its holdings in shares of Hims & Hers Health by 1.8% in the third quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company's stock valued at $793,000 after purchasing an additional 252 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of Hims & Hers Health by 44.7% in the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company's stock valued at $54,000 after purchasing an additional 283 shares during the period. Finally, W.G. Shaheen & Associates DBA Whitney & Co increased its position in Hims & Hers Health by 4.8% during the third quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 7,695 shares of the company's stock worth $436,000 after purchasing an additional 350 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on the company. Evercore set a $24.00 price target on Hims & Hers Health in a research report on Tuesday, February 24th. Bank of America raised shares of Hims & Hers Health from an "underperform" rating to a "neutral" rating and raised their price objective for the stock from $12.50 to $23.00 in a research note on Tuesday, March 10th. Truist Financial reaffirmed a "hold" rating and set a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a report on Tuesday, February 24th. Citigroup upgraded shares of Hims & Hers Health from a "sell" rating to a "neutral" rating and boosted their target price for the company from $13.25 to $24.00 in a research note on Tuesday, March 10th. Finally, Needham & Company LLC raised shares of Hims & Hers Health from a "hold" rating to a "buy" rating and set a $30.00 price target on the stock in a report on Monday, March 9th. Three analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $31.29.
Check Out Our Latest Analysis on Hims & Hers Health
Key Hims & Hers Health News
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: Partnership with Novo Nordisk opens a pre‑launch waitlist for Ozempic and Wegovy, giving HIMS direct access to high‑demand branded GLP‑1s via its telehealth platform — a clear revenue growth opportunity and a resolution of prior disputes with Novo. Novo Nordisk Partners With Hims & Hers — Yahoo Finance
- Positive Sentiment: Sell‑side optimism: at least one research note cited in the press forecasts meaningful upside for HIMS, which could support longer‑term investor sentiment if execution on GLP‑1 access drives subscription and prescription volume. Leerink Forecasts Strong Price Appreciation — AmericanBankingNews
- Neutral Sentiment: Industry pieces and investor commentary are highlighting HIMS among telehealth/weight‑loss winners; these are background for interest but don’t by themselves change fundamentals. Seeking Alpha: Value Investing With Raul Shah
- Negative Sentiment: Insider selling: multiple insiders (including COO Michael Chi) disclosed sizable stock sales on March 17th — large insider dispositions can signal near‑term owner liquidity or reduced conviction and often weigh on sentiment. SEC Form 4 — Michael Chi SEC Form 4 — Soleil Boughton
- Negative Sentiment: Pricing risk for GLP‑1s: analysts note pricing competition between major players (Novo Nordisk vs. Eli Lilly) will increasingly be a factor — lower prices or faster discounting could pressure gross margins and ARPU from new GLP‑1 prescriptions. Health Care Roundup — Yahoo Finance
- Negative Sentiment: Near‑term price reaction: trade commentary and market reports show HIMS underperformed the broader market in the latest session, indicating short‑term selling pressure even as strategic positives remain. Zacks — HIMS Suffers Larger Drop
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.
The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
